Prevention and management of obinutuzumab-associated toxicities: Australian experience-Reference-Cited by-同舟云学术

Prevention and management of obinutuzumab-associated toxicities: Australian experience

Published:2015-12 Issue: Volume:21 Page:15-27
ISSN:1322-7114
Container-title:International Journal of Nursing Practice
language:en
Short-container-title:International Journal of Nursing Practice

Author:

Snowden Alicia¹,Hayden Ingrid²,Dixon Joanna³,Gregory Gareth⁴

Affiliation:

1. Peter MacCallum Cancer Centre; Melbourne Australia

2. St John of God Subiaco Hospital; Perth Australia

3. Roche Products Pty. Ltd, Dee Why; NSW Australia

4. Monash Haematology, Monash Health; Clayton Victoria Australia

Publisher

Wiley

Subject

General Nursing

Reference32 articles.

1. World Health Organization classification of tumors of hematopoietic and lymphoid tissues, 4th edition, 2008 - major changes from the 3rd edition, 2001;Zerbini;Revista da Associação Médica Brasileira,2011

2. CD20 and CD5 expression in B-chronic lymphocytic leukemia;Marti;Annals of the New York Academy of Sciences,1992

3. National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)®

4. National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) database http://seer.cancer.gov

5. Australian Institute of Health and Welfare (AIHW) Australian Cancer Incidence and Mortality (ACIM) book for chronic lymphocytic leukaemia www.aihw.gov.au/WorkArea/DownloadAsset.aspx?id=60129546393

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety of a 90-min duration of intravenous infusion of obinutuzumab in patients with B-cell non-Hodgkin's lymphoma in a tertiary hospital in China: a prospective, open-label, exploratory clinical trial;Brazilian Journal of Medical and Biological Research;2024

2. Real-world time to discontinuation of first-line venetoclax + obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma;Current Medical Research and Opinion;2023-08-21

3. Therapeutic Management of Chronic Lymphocytic Leukemia Presenting with Recurrent Massive Ascites;Current Oncology;2022-09-22

4. Search for Risk Factors Influencing the Occurrence of Infusion Reaction after Initial Treatment with Obinutuzumab;Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences);2021-11-10

The importance of early identification of infusion-related reactions to monoclonal antibodies

;Therapeutics and Clinical Risk Management;2019-08